KalVista Pharmaceuticals
KALV
KALV
128 hedge funds and large institutions have $557M invested in KalVista Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 46 funds opening new positions, 33 increasing their positions, 35 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
128
Holders Change
+35
Holders Change %
+37.63%
% of All Funds
1.86%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
46
Increased
33
Reduced
35
Closed
11
Calls
$1.02M
Puts
$7.04M
Net Calls
-$6.02M
Net Calls Change
-$16.1M
Top Buyers
| 1 |
VA
VR Adviser
New York
|
+$25.6M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$22.2M |
| 3 |
SCM
Suvretta Capital Management
New York
|
+$17.9M |
| 4 |
Capital World Investors
Los Angeles,
California
|
+$17.4M |
| 5 |
FTM
First Turn Management
Del Mar,
California
|
+$14M |
Top Sellers
| 1 |
TCM
TCG Crossover Management
Palo Alto,
California
|
-$26.5M |
| 2 |
JFG
Jefferies Financial Group
New York
|
-$12.4M |
| 3 |
VC
Vivo Capital
Palo Alto,
California
|
-$10.5M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$8.26M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$5.78M |
